<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113109</url>
  </required_header>
  <id_info>
    <org_study_id>#191228</org_study_id>
    <nct_id>NCT04113109</nct_id>
  </id_info>
  <brief_title>Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2</brief_title>
  <official_title>Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LCZ696, a molecular complex of the angiotensin receptor blocker (ARB) valsartan with an&#xD;
      inhibitor of neprilysin (NEP, neutral endopeptidase-24.11) sacubitril improved mortality&#xD;
      compared to enalapril in patients with heart failure (HF), reduced ejection fraction (EF),&#xD;
      and increased brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) in the&#xD;
      PARADIGM-HF trial.1 The PIONEER-HF study demonstrated the efficacy of LCZ696 in preventing&#xD;
      rehospitalization in patients with acutely decompensated HF.2&#xD;
&#xD;
      LCZ696 has been underutilized in heart failure, in part due to concerns about hypotension.&#xD;
      NEP degrades several vasodilator peptides including bradykinin, substance P and brain-type&#xD;
      natriuretic peptide. Decreased degradation of endogenous bradykinin could contribute to&#xD;
      hypotension at initiation of LCZ696 through vasodilation or through increased natriuresis and&#xD;
      diuresis. Inhibition of the bradykinin B2 receptor using icatibant would be expected to&#xD;
      prevent this effect.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
      The main objectives of this mechanistic randomized, double-blind, crossover-design study are:&#xD;
&#xD;
        -  The primary objective is to test the hypothesis that endogenous bradykinin contributes&#xD;
           to effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis at&#xD;
           initiation.&#xD;
&#xD;
        -  The secondary objective is to test the hypothesis endogenous bradykinin contributes to&#xD;
           effects of ARB/NEP inhibition on blood pressure, natriuresis, and diuresis after&#xD;
           up-titration.&#xD;
&#xD;
      Eighty (80) subjects with stable heart failure who meet all inclusion/exclusion criteria will&#xD;
      be enrolled. Subjects who qualify will collect their urine for 24 hours before each study day&#xD;
      for measurement of volume, sodium and potassium. At the start of the study, they will stop&#xD;
      their regular angiotensin-converting enzyme (ACE) inhibitor or ARB. After a 48-hour washout,&#xD;
      they will undergo a study day in which they are given a single dose of 50 mg LCZ696. They&#xD;
      will also receive either the bradykinin B2 receptor antagonist icatibant or placebo vehicle&#xD;
      in random order (double-blind). After a 96-hour washout, they will repeat the study day and&#xD;
      receive a single dose of 50 mg LCZ696 and the opposite study drug (icatibant or placebo).&#xD;
      After completion of the two acute study days, subjects will take LCZ696 50 mg bid for two&#xD;
      weeks, followed by LCZ696 100 mg bid for three weeks, and then LCZ696 200 mg bid, following&#xD;
      the conservative up-titration protocol from the TITRATION study.3 Criteria for continuing&#xD;
      up-titration appear in the full study protocol. On the 7th and 10th day of the 200 mg bid or&#xD;
      highest tolerated dose, subjects will again undergo two more study days three days apart in&#xD;
      which they are randomized to receive either icatibant or vehicle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean arterial pressure</measure>
    <time_frame>Eight hours</time_frame>
    <description>Mean arterial pressure (MAP) will be measured before and after administration of LCZ696 on each of the four study days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine sodium excretion</measure>
    <time_frame>Total urine output from drug administration to six hours following drug administration</time_frame>
    <description>Urine sodium excretion will be measured for six hours following study LCZ696 on each of the four study days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Over six hours on each of four study days</time_frame>
    <description>Heart rate (HR) will be measured before and after LCZ696 on each of the four study days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine volume</measure>
    <time_frame>Over six hours on each of four study days</time_frame>
    <description>Urine volume will be measured for six hours following LCZ696 on each of the four study days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal plasma flow</measure>
    <time_frame>Over six hours on each of four study days</time_frame>
    <description>Renal plasma flow (RPF) will be calculated from para-aminohippurate clearance prior to and following LCZ696.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>Over six hours on each of four study days</time_frame>
    <description>Glomerular filtration rate (GFR) will be calculated from the clearance of iohexol prior to and following LCZ66 on each of the four study days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine albumin-to-creatinine ratio</measure>
    <time_frame>Through study completion, an average of 49 days</time_frame>
    <description>Urine albumin-to-creatinine ratio (UACR) will be calculated before and after LCZ696 on each of the four study days.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>placebo, icatibant, placebo, icatibant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, icatibant, icatibant, placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and placebo (vehicle). After a 96-hr washout period, subjects will be given LCZ696 50 mg and icatibant. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>icatibant, placebo, placebo, icatibant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive placebo and icatibant, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>icatibant, placebo, icatibant placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 48-hr washout, participants in this arm will be given LCZ696 50 mg and icatibant. After a 96-hr washout period, subjects will be given LCZ696 50 mg and placebo. Participants will then undergo uptitration of LCZ696 over seven weeks. On the 7th and 10th days of the 200 mg bid or highest tolerated dose of LCZ696, participants in this arm will receive icatibant and placebo, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ 696</intervention_name>
    <description>Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).</description>
    <arm_group_label>icatibant, placebo, icatibant placebo</arm_group_label>
    <arm_group_label>icatibant, placebo, placebo, icatibant</arm_group_label>
    <arm_group_label>placebo, icatibant, icatibant, placebo</arm_group_label>
    <arm_group_label>placebo, icatibant, placebo, icatibant</arm_group_label>
    <other_name>Entresto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icatibant</intervention_name>
    <description>Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.</description>
    <arm_group_label>icatibant, placebo, icatibant placebo</arm_group_label>
    <arm_group_label>icatibant, placebo, placebo, icatibant</arm_group_label>
    <arm_group_label>placebo, icatibant, icatibant, placebo</arm_group_label>
    <arm_group_label>placebo, icatibant, placebo, icatibant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo (vehicle) will be given at the same rate as icatibant.</description>
    <arm_group_label>icatibant, placebo, icatibant placebo</arm_group_label>
    <arm_group_label>icatibant, placebo, placebo, icatibant</arm_group_label>
    <arm_group_label>placebo, icatibant, icatibant, placebo</arm_group_label>
    <arm_group_label>placebo, icatibant, placebo, icatibant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Para-aminohippurate</intervention_name>
    <description>Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.</description>
    <arm_group_label>icatibant, placebo, icatibant placebo</arm_group_label>
    <arm_group_label>icatibant, placebo, placebo, icatibant</arm_group_label>
    <arm_group_label>placebo, icatibant, icatibant, placebo</arm_group_label>
    <arm_group_label>placebo, icatibant, placebo, icatibant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.</description>
    <arm_group_label>icatibant, placebo, icatibant placebo</arm_group_label>
    <arm_group_label>icatibant, placebo, placebo, icatibant</arm_group_label>
    <arm_group_label>placebo, icatibant, icatibant, placebo</arm_group_label>
    <arm_group_label>placebo, icatibant, placebo, icatibant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Black and white men and women&#xD;
&#xD;
          2. Stable patients with a reduced ejection fraction (EF)&#xD;
&#xD;
               1. EF ≤40%, and&#xD;
&#xD;
               2. history of symptoms of New York Heart Association (NYHA) class I, II, or III&#xD;
                  heart failure (HF)&#xD;
&#xD;
               3. stable clinical symptoms including no hospitalizations for the last six months&#xD;
&#xD;
               4. who are not already taking LCZ696&#xD;
&#xD;
          3. treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEi) or&#xD;
             angiotensin receptor blocker (ARB) and with a beta blocker (unless contraindicated or&#xD;
             not tolerated) for at least four weeks&#xD;
&#xD;
          4. for patients with NYHA Class II or III HF, treatment with a stable dose of an&#xD;
             mineralocorticoid receptor (MR) antagonist for at least four weeks, unless not&#xD;
             possible due to renal function or serum potassium.&#xD;
&#xD;
          5. For female subjects, the following conditions must be met:&#xD;
&#xD;
               1. postmenopausal status for at least one year, or&#xD;
&#xD;
               2. status post-surgical sterilization&#xD;
&#xD;
               3. or if of childbearing potential, utilization of barrier methods of birth control&#xD;
                  or an oral contraceptive and willingness to undergo urine β- human chorionic&#xD;
                  gonadotropin (HCG) testing on every study day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar&#xD;
             chemical classes, ACEi, ARBs, or neutral endopeptidase inhibitor (NEPi), as well as&#xD;
             known or suspected contraindications to the study drugs&#xD;
&#xD;
          2. History of angioedema&#xD;
&#xD;
          3. History of decompensated HF within the last three months (exacerbation of chronic HF&#xD;
             manifested by signs and symptoms that required intravenous therapy or hospitalization)&#xD;
&#xD;
          4. History of heart transplant or on a transplant list or with left ventricular&#xD;
             assistance device&#xD;
&#xD;
          5. Symptomatic hypotension and/or a systolic blood pressure (SBP)&lt;100 mmHg at screening&#xD;
             or &lt;95 mmHg during the study&#xD;
&#xD;
          6. Serum potassium &gt;5.2 mmol/L at screening or &gt;5.4 mmol/L during the study&#xD;
&#xD;
          7. Impaired renal function (eGFR of &lt;30mL/min/1.73 m2) as determined by the four-variable&#xD;
             Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is&#xD;
             expressed in mg/dL and age in years:&#xD;
&#xD;
             eGFR (mL/min/1.73 m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if&#xD;
             female)&#xD;
&#xD;
          8. Acute coronary syndrome, cardiac, carotid, or other major cardiovascular surgery,&#xD;
             percutaneous coronary intervention, or carotid angioplasty within six months prior to&#xD;
             screening&#xD;
&#xD;
          9. Coronary or carotid artery disease likely to require surgical or percutaneous&#xD;
             intervention within six months of screening&#xD;
&#xD;
         10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or&#xD;
             transient ischemic attack&#xD;
&#xD;
         11. History of ventricular arrhythmia with syncopal episodes&#xD;
&#xD;
         12. Symptomatic bradycardia or second- or third-degree atrioventricular block without a&#xD;
             pacemaker&#xD;
&#xD;
         13. Presence of hemodynamically significant mitral and/or aortic valve disease, except&#xD;
             mitral regurgitation secondary to left ventricle (LV) dilatation&#xD;
&#xD;
         14. Presence of other hemodynamically significant obstructive lesions of the LV outflow&#xD;
             tract, including aortic and subaortic stenosis&#xD;
&#xD;
         15. Type 1 diabetes&#xD;
&#xD;
         16. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c &gt;9%&#xD;
&#xD;
         17. In T2DM, dipeptidyl peptidase-4 inhibitor use for one month prior to enrollment will&#xD;
             be excluded due to possible interaction with LCZ696&#xD;
&#xD;
         18. Hematocrit &lt;35%&#xD;
&#xD;
         19. Breast feeding and pregnancy&#xD;
&#xD;
         20. History or presence of immunological or hematological disorders&#xD;
&#xD;
         21. History of malignancy not felt to be cured, except non-melanoma skin cancer&#xD;
&#xD;
         22. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week&#xD;
&#xD;
         23. History of hypersensitivity reaction to contrast&#xD;
&#xD;
         24. Clinically significant gastrointestinal impairment that could interfere with drug&#xD;
             absorption&#xD;
&#xD;
         25. History of pancreatitis or known pancreatic lesions&#xD;
&#xD;
         26. Impaired hepatic function [aspartate amino transaminase (AST) and/or alanine amino&#xD;
             transaminase (ALT) &gt;3.0 x upper limit of normal range]&#xD;
&#xD;
         27. Any underlying or acute disease requiring regular medication which could possibly pose&#xD;
             a threat to the subject or make implementation of the protocol or interpretation of&#xD;
             the study results difficult, such as arthritis treated with non-steroidal&#xD;
             anti-inflammatory drugs&#xD;
&#xD;
         28. Treatment with chronic systemic glucocorticoid therapy within the last year&#xD;
&#xD;
         29. Treatment with lithium salts&#xD;
&#xD;
         30. History of alcohol or drug abuse&#xD;
&#xD;
         31. Treatment with any investigational drug in the one month preceding the study&#xD;
&#xD;
         32. Mental conditions rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study&#xD;
&#xD;
         33. Inability to comply with the protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J. Brown, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynne W. Stevenson, M.D.</last_name>
    <phone>615-544-5112</phone>
    <email>lynne.w.stevenson@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erica M. Dillon, M.D.</last_name>
    <phone>615-544-5112</phone>
    <email>Erica.m.dillon@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.</citation>
    <PMID>25176015</PMID>
  </reference>
  <reference>
    <citation>Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090.</citation>
    <PMID>30415601</PMID>
  </reference>
  <reference>
    <citation>Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova-Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez-Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gómez-Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep;18(9):1193-202. doi: 10.1002/ejhf.548. Epub 2016 May 12.</citation>
    <PMID>27170530</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icatibant</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

